Folotyn for Non-Hodgkin's Lymphoma Riverhead NY

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Local Companies

Jiyeon Kim, MD
631-758-7575
285 Sills Rd Bldg 16
East Patchogue, NY
Marilyn A Mc Laughlin, MD
631-727-7100
36 Osprey Ave
Riverhead, NY
Louis J Avvento, MD
631-727-8500
1333 E Main St
Riverhead, NY
Sheryl Green, MD
631-475-8846
285 Sills Rd
East Patchogue, NY
Anjali Sharma, MD
732-915-7789
208A Beaumont Pl
Coram, NY
LOUIS AVVENTO, MD
(631) 727-8827
1333 E Main Street
Riverhead, NY
Margie A Lewis, MD
631-474-6183
PO Box 2041
Miller Place, NY
Barry Leslie Strauss, MD
631-283-6611
353 Meeting House Ln
Southampton, NY
Alexander A Tocher, MD
595 Route 25a
Miller Place, NY
Susan S Emanuele, MD
631-727-7100
36 Osprey Ave
Riverhead, NY
Data Provided by:
  

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Donor Stem-Cell Transplant for Acute Myeloid Leukemia Riverhead NY
For most patients with acute myeloid leukemia (AML) who come out of remission, donor stem cells appear to offer the best shot at survival, a new analysis shows.
- Green Tea and Hematologic Malignancies Riverhead NY